25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Celyad SA
Buy, Hold or Sell?

Let's analyze Celyad together

I guess you are interested in Celyad SA. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Celyad SA. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Celyad SA

I send you an email if I find something interesting about Celyad SA.

Quick analysis of Celyad (30 sec.)










What can you expect buying and holding a share of Celyad? (30 sec.)

How much money do you get?

How much money do you get?
‚ā¨0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
‚ā¨-0.25
Expected worth in 1 year
‚ā¨-1.66
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
‚ā¨-1.41
Return On Investment
-556.7%

For what price can you sell your share?

Current Price per Share
‚ā¨0.25
Expected price per share
‚ā¨0.231 - ‚ā¨0.291
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

1. Valuation of Celyad (5 min.)




Live pricePrice per Share (EOD)

‚ā¨0.25

Intrinsic Value Per Share

‚ā¨-5.42 - ‚ā¨-0.62

Total Value Per Share

‚ā¨-5.67 - ‚ā¨-0.87

2. Growth of Celyad (5 min.)




Is Celyad growing?

Current yearPrevious yearGrowGrow %
How rich?-$11.1m$4.6m-$15.8m-141.8%

How much money is Celyad making?

Current yearPrevious yearGrowGrow %
Making money-$9.1m-$44.3m$35.2m384.6%
Net Profit Margin-8,282.4%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Celyad (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#920 / 982

Most Revenue
#675 / 982

Most Profit
#551 / 982

Most Efficient
#894 / 982
3rd party ad coffee SUPPORTERis ad-free.

What can you expect buying and holding a share of Celyad? (5 min.)

Welcome investor! Celyad's management wants to use your money to grow the business. In return you get a share of Celyad.

What can you expect buying and holding a share of Celyad?

First you should know what it really means to hold a share of Celyad. And how you can make/lose money.

Speculation

The Price per Share of Celyad is ‚ā¨0.254. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Celyad.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Celyad, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ‚ā¨-0.25. Based on the TTM, the Book Value Change Per Share is ‚ā¨-0.35 per quarter. Based on the YOY, the Book Value Change Per Share is ‚ā¨-0.95 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ‚ā¨0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Celyad.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share
Usd Eps-0.22-87.1%-0.22-87.1%-1.07-421.8%-0.64-250.9%-0.75-293.4%
Usd Book Value Change Per Share-0.38-150.9%-0.38-150.9%-1.03-405.2%-0.35-135.9%-0.07-28.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.38-150.9%-0.38-150.9%-1.03-405.2%-0.35-135.9%-0.07-28.1%
Usd Price Per Share0.42-0.42-0.55-4.50-18.66-
Price to Earnings Ratio-1.91--1.91--0.51--7.58--26.72-
Price-to-Total Gains Ratio-1.10--1.10--0.53--9.84-13.44-
Price to Book Ratio-1.56--1.56-4.86-4.86-14.56-
Price-to-Total Gains Ratio-1.10--1.10--0.53--9.84-13.44-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.2754376
Number of shares3630
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.38-0.35
Usd Total Gains Per Share-0.38-0.35
Gains per Quarter (3630 shares)-1,391.41-1,252.61
Gains per Year (3630 shares)-5,565.65-5,010.45
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-5566-55760-5010-5020
20-11131-111420-10021-10030
30-16697-167080-15031-15040
40-22263-222740-20042-20050
50-27828-278400-25052-25060
60-33394-334060-30063-30070
70-38960-389720-35073-35080
80-44525-445380-40084-40090
90-50091-501040-45094-45100
100-55656-556700-50104-50110

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.013.01.00.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%4.06.00.040.0%6.08.00.042.9%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.014.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%4.06.00.040.0%6.08.00.042.9%
3rd party ad coffee SUPPORTERis ad-free.

Fundamentals of Celyad

About Celyad SA

Celyad Oncology SA, a biopharmaceutical company, focuses on the research and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. The company is developing shRNA non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the TCR without the need for gene editing; multi-specific CAR T-cell platform that focuses on the NKG2D receptor; NKG2D-based CAR T-cell therapies; and B7-H6 targeting CAT T-cell therapies. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery/PerkinElmer for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

Fundamental data was last updated by Penke on 2024-07-07 23:25:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

1.1. Profitability of Celyad SA.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit¬†Celyad earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare¬†Celyad to the¬†Biotechnology industry mean.
  • A Net Profit Margin of -8,282.4%¬†means that¬†€-82.82 for each €1¬†in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Celyad SA:

  • The MRQ is -8,282.4%. The company is making a huge loss. -2
  • The TTM is -8,282.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-8,282.4%TTM-8,282.4%0.0%
TTM-8,282.4%YOY--8,282.4%
TTM-8,282.4%5Y-167,100.5%+158,818.1%
5Y-167,100.5%10Y-182,027.4%+14,926.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8,282.4%-168.6%-8,113.8%
TTM-8,282.4%-209.9%-8,072.5%
YOY--235.1%+235.1%
5Y-167,100.5%-390.8%-166,709.7%
10Y-182,027.4%-505.1%-181,522.3%
1.1.2. Return on Assets

Shows how efficient Celyad is using its assets to generate profit.

  • Above 5% is considered healthy¬†but always compare¬†Celyad to the¬†Biotechnology industry mean.
  • -51.9% Return on Assets means that¬†Celyad generated¬†€-0.52 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Celyad SA:

  • The MRQ is -51.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -51.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-51.9%TTM-51.9%0.0%
TTM-51.9%YOY-207.6%+155.7%
TTM-51.9%5Y-70.2%+18.3%
5Y-70.2%10Y-53.5%-16.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-51.9%-11.7%-40.2%
TTM-51.9%-11.8%-40.1%
YOY-207.6%-11.2%-196.4%
5Y-70.2%-13.2%-57.0%
10Y-53.5%-14.6%-38.9%
1.1.3. Return on Equity

Shows how efficient Celyad is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare¬†Celyad to the¬†Biotechnology industry mean.
  • 0.0% Return on Equity means Celyad generated €0.00¬†for each¬†€1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Celyad SA:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-948.2%+948.2%
TTM-5Y-225.6%+225.6%
5Y-225.6%10Y-142.6%-83.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--14.0%+14.0%
TTM--15.2%+15.2%
YOY-948.2%-14.0%-934.2%
5Y-225.6%-18.8%-206.8%
10Y-142.6%-19.3%-123.3%
3rd party ad coffee SUPPORTERis ad-free.

1.2. Operating Efficiency of Celyad SA.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Celyad is operating .

  • Measures how much profit Celyad makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare¬†Celyad to the¬†Biotechnology industry mean.
  • An Operating Margin of -10,389.2%¬†means the company generated €-103.89 ¬†for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Celyad SA:

  • The MRQ is -10,389.2%. The company is operating very inefficient. -2
  • The TTM is -10,389.2%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-10,389.2%TTM-10,389.2%0.0%
TTM-10,389.2%YOY--10,389.2%
TTM-10,389.2%5Y-204,943.8%+194,554.6%
5Y-204,943.8%10Y-200,249.9%-4,693.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10,389.2%-351.1%-10,038.1%
TTM-10,389.2%-224.3%-10,164.9%
YOY--243.1%+243.1%
5Y-204,943.8%-396.3%-204,547.5%
10Y-200,249.9%-510.1%-199,739.8%
1.2.2. Operating Ratio

Measures how efficient Celyad is keeping operating costs low.

  • Below 1 is considered healthy (always compare to¬†Biotechnology industry mean).
  • An Operation Ratio of 104.89 means that the operating costs are €104.89 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Celyad SA:

  • The MRQ is 104.892. The company is inefficient in keeping operating costs low. -1
  • The TTM is 104.892. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ104.892TTM104.8920.000
TTM104.892YOY-+104.892
TTM104.8925Y2,050.038-1,945.146
5Y2,050.03810Y2,243.218-193.179
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ104.8923.004+101.888
TTM104.8923.255+101.637
YOY-3.484-3.484
5Y2,050.0385.004+2,045.034
10Y2,243.2186.533+2,236.685
3rd party ad coffee SUPPORTERis ad-free.

1.3. Liquidity of Celyad SA.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Celyad is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to¬†Biotechnology industry mean).
  • A Current Ratio of 3.79¬†means the company has €3.79 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Celyad SA:

  • The MRQ is 3.793. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.793. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.793TTM3.7930.000
TTM3.793YOY1.422+2.371
TTM3.7935Y2.591+1.202
5Y2.59110Y4.543-1.952
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.7933.7930.000
TTM3.7934.052-0.259
YOY1.4224.945-3.523
5Y2.5915.990-3.399
10Y4.5436.326-1.783
1.3.2. Quick Ratio

Measures if Celyad is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but¬†always compare¬†Celyad to the¬†Biotechnology industry mean.
  • A Quick Ratio of 3.34¬†means the company can pay off €3.34 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Celyad SA:

  • The MRQ is 3.337. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.337. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.337TTM3.3370.000
TTM3.337YOY1.314+2.023
TTM3.3375Y2.410+0.927
5Y2.41010Y5.010-2.600
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.3373.186+0.151
TTM3.3373.581-0.244
YOY1.3144.803-3.489
5Y2.4105.922-3.512
10Y5.0106.430-1.420
3rd party ad coffee SUPPORTERis ad-free.

1.4. Solvency of Celyad SA.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Celyad assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare¬†Celyad to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.63¬†means that Celyad assets are¬†financed with 163.4% credit (debt) and the remaining percentage (100% - 163.4%)¬†is financed by its owners/shareholders.¬†

Let's take a look of the Debt to Asset Ratio trends of Celyad SA:

  • The MRQ is 1.634. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.634. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.634TTM1.6340.000
TTM1.634YOY0.781+0.853
TTM1.6345Y0.779+0.856
5Y0.77910Y0.573+0.205
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6340.330+1.304
TTM1.6340.340+1.294
YOY0.7810.287+0.494
5Y0.7790.368+0.411
10Y0.5730.383+0.190
1.4.2. Debt to Equity Ratio

Measures if Celyad is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but¬†always compare¬†Celyad to the¬†Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has €0.00 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Celyad SA:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY3.567-3.567
TTM-5Y1.300-1.300
5Y1.30010Y0.944+0.356
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.366-0.366
TTM-0.415-0.415
YOY3.5670.369+3.198
5Y1.3000.441+0.859
10Y0.9440.483+0.461
3rd party ad coffee SUPPORTERis ad-free.

2. Market Valuation of Celyad SA

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures¬†how much money you pay¬†for each share for¬†every €1 in earnings Celyad generates.

  • Above 15 is considered overpriced but¬†always compare¬†Celyad to the¬†Biotechnology industry mean.
  • A PE ratio of -1.91 means the investor is paying €-1.91¬†for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Celyad SA:

  • The EOD is -1.246. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.913. Based on the earnings, the company is expensive. -2
  • The TTM is -1.913. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.246MRQ-1.913+0.667
MRQ-1.913TTM-1.9130.000
TTM-1.913YOY-0.512-1.400
TTM-1.9135Y-7.579+5.666
5Y-7.57910Y-26.717+19.138
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.246-2.610+1.364
MRQ-1.913-3.020+1.107
TTM-1.913-2.891+0.978
YOY-0.512-3.549+3.037
5Y-7.579-6.222-1.357
10Y-26.717-6.322-20.395
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Celyad SA:

  • The EOD is -0.652. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.001. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.001. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.652MRQ-1.001+0.349
MRQ-1.001TTM-1.0010.000
TTM-1.001YOY-0.745-0.256
TTM-1.0015Y-6.175+5.174
5Y-6.17510Y-25.992+19.817
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.652-3.139+2.487
MRQ-1.001-3.748+2.747
TTM-1.001-3.717+2.716
YOY-0.745-5.038+4.293
5Y-6.175-7.998+1.823
10Y-25.992-8.522-17.470
3rd party ad coffee SUPPORTERis ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Celyad is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy¬†(always compare to Biotechnology industry mean).
  • A PB ratio of -1.56 means the investor is paying €-1.56¬†for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Celyad SA:

  • The EOD is -1.019. Based on the equity, the company is expensive. -2
  • The MRQ is -1.565. Based on the equity, the company is expensive. -2
  • The TTM is -1.565. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.019MRQ-1.565+0.546
MRQ-1.565TTM-1.5650.000
TTM-1.565YOY4.856-6.420
TTM-1.5655Y4.857-6.422
5Y4.85710Y14.555-9.698
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.0191.928-2.947
MRQ-1.5652.247-3.812
TTM-1.5652.301-3.866
YOY4.8562.387+2.469
5Y4.8573.674+1.183
10Y14.5554.139+10.416
2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Celyad SA compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.353-0.3530%-0.949+169%-0.318-10%-0.066-81%
Book Value Per Share---0.249-0.2490%0.104-339%0.552-145%1.078-123%
Current Ratio--3.7933.7930%1.422+167%2.591+46%4.543-17%
Debt To Asset Ratio--1.6341.6340%0.781+109%0.779+110%0.573+185%
Debt To Equity Ratio----0%3.567-100%1.300-100%0.944-100%
Dividend Per Share----0%-0%-0%-0%
Eps---0.204-0.2040%-0.988+385%-0.588+188%-0.687+237%
Free Cash Flow Per Share---0.389-0.3890%-0.679+74%-0.618+59%-0.676+74%
Free Cash Flow To Equity Per Share---0.164-0.1640%-0.601+267%-0.253+54%-0.045-73%
Gross Profit Margin--1.0251.0250%1.006+2%1.019+1%1.021+0%
Intrinsic Value_10Y_max---0.619--------
Intrinsic Value_10Y_min---5.421--------
Intrinsic Value_1Y_max---0.464--------
Intrinsic Value_1Y_min---0.649--------
Intrinsic Value_3Y_max---1.089--------
Intrinsic Value_3Y_min---1.871--------
Intrinsic Value_5Y_max---1.344--------
Intrinsic Value_5Y_min---2.995--------
Market Cap10522864.400-54%16157154.00016157154.0000%20962871.600-23%171771261.320-91%712741777.260-98%
Net Profit Margin---82.824-82.8240%--100%-1671.005+1918%-1820.274+2098%
Operating Margin---103.892-103.8920%--100%-2049.438+1873%-2002.499+1827%
Operating Ratio--104.892104.8920%-+100%2050.038-95%2243.218-95%
Pb Ratio-1.019+35%-1.565-1.5650%4.856-132%4.857-132%14.555-111%
Pe Ratio-1.246+35%-1.913-1.9130%-0.512-73%-7.579+296%-26.717+1297%
Price Per Share0.254-54%0.3900.3900%0.506-23%4.146-91%17.204-98%
Price To Free Cash Flow Ratio-0.652+35%-1.001-1.0010%-0.745-26%-6.175+517%-25.992+2496%
Price To Total Gains Ratio-0.719+35%-1.103-1.1030%-0.533-52%-9.836+791%13.441-108%
Quick Ratio--3.3373.3370%1.314+154%2.410+38%5.010-33%
Return On Assets---0.519-0.5190%-2.076+300%-0.702+35%-0.535+3%
Return On Equity----0%-9.4820%-2.2560%-1.4260%
Total Gains Per Share---0.353-0.3530%-0.949+169%-0.318-10%-0.066-81%
Usd Book Value---11198598.800-11198598.8000%4681354.800-339%24776804.960-145%48408375.080-123%
Usd Book Value Change Per Share---0.383-0.3830%-1.029+169%-0.345-10%-0.071-81%
Usd Book Value Per Share---0.270-0.2700%0.113-339%0.598-145%1.168-123%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.221-0.2210%-1.071+385%-0.637+188%-0.745+237%
Usd Free Cash Flow---17497878.400-17497878.4000%-30507425.200+74%-27785147.440+59%-30385104.880+74%
Usd Free Cash Flow Per Share---0.422-0.4220%-0.736+74%-0.671+59%-0.733+74%
Usd Free Cash Flow To Equity Per Share---0.177-0.1770%-0.652+267%-0.274+54%-0.049-73%
Usd Market Cap11410994.155-54%17520817.79817520817.7980%22732137.963-23%186268755.775-91%772897183.261-98%
Usd Price Per Share0.275-54%0.4230.4230%0.549-23%4.496-91%18.656-98%
Usd Profit---9161011.200-9161011.2000%-44389914.000+385%-26465432.640+189%-30787091.960+236%
Usd Revenue--110608.800110608.8000%-+100%24507.440+351%1674313.600-93%
Usd Total Gains Per Share---0.383-0.3830%-1.029+169%-0.345-10%-0.071-81%
 EOD+2 -6MRQTTM+0 -0YOY+22 -115Y+20 -1310Y+14 -19

3.2. Fundamental Score

Let's check the fundamental score of Celyad SA based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.246
Price to Book Ratio (EOD)Between0-1-1.019
Net Profit Margin (MRQ)Greater than0-82.824
Operating Margin (MRQ)Greater than0-103.892
Quick Ratio (MRQ)Greater than13.337
Current Ratio (MRQ)Greater than13.793
Debt to Asset Ratio (MRQ)Less than11.634
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.519
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Celyad SA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.775
Ma 20Greater thanMa 500.268
Ma 50Greater thanMa 1000.289
Ma 100Greater thanMa 2000.314
OpenGreater thanClose0.252
Total0/5 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-12-312020-12-312021-12-312022-12-312023-12-31
Total Stockholder Equity 45,619-14,62530,99412,64543,639-39,3224,317-14,644-10,327
Net Debt  -34,97521,379-13,596-13,790-27,38615,196-12,19022,87510,685



Latest Balance Sheet

Balance Sheet of 2023-12-31. All numbers in thousands.

Summary
Total Assets16,282
Total Liabilities26,609
Total Stockholder Equity-10,327
 As reported
Total Liabilities 26,609
Total Stockholder Equity+ -10,327
Total Assets = 16,282

Assets

Total Assets16,282
Total Current Assets11,121
Long-term Assets5,161
Total Current Assets
Cash And Cash Equivalents 7,004
Net Receivables 2,780
Other Current Assets 1,337
Total Current Assets  (as reported)11,121
Total Current Assets  (calculated)11,121
+/-0
Long-term Assets
Property Plant Equipment 1,830
Intangible Assets 48
Long-term Assets Other 2,941
Long-term Assets  (as reported)5,161
Long-term Assets  (calculated)4,819
+/- 342

Liabilities & Shareholders' Equity

Total Current Liabilities2,932
Long-term Liabilities23,677
Total Stockholder Equity-10,327
Total Current Liabilities
Short-term Debt 156
Accounts payable 1,243
Other Current Liabilities 1,024
Total Current Liabilities  (as reported)2,932
Total Current Liabilities  (calculated)2,423
+/- 509
Long-term Liabilities
Long-term Liabilities  (as reported)23,677
Long-term Liabilities  (calculated)0
+/- 23,677
Total Stockholder Equity
Common Stock32,949
Retained Earnings -358,372
Accumulated Other Comprehensive Income 315,096
Other Stockholders Equity 0
Total Stockholder Equity (as reported)-10,327
Total Stockholder Equity (calculated)-10,327
+/-0
Other
Cash and Short Term Investments 7,004
Common Stock Shares Outstanding 25,722
Current Deferred Revenue509
Liabilities and Stockholders Equity 16,282
Net Debt 10,685
Net Working Capital 8,189
Short Long Term Debt Total 17,689



Balance Sheet

All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-31
> Total Assets 
17,495
6,877
13,746
32,386
43,976
159,525
138,805
77,626
94,299
89,836
66,084
79,943
19,716
16,282
16,28219,71679,94366,08489,83694,29977,626138,805159,52543,97632,38613,7466,87717,495
   > Total Current Assets 
0
3,469
2,192
22,602
32,935
109,419
85,367
36,394
51,692
42,836
19,705
34,292
14,825
11,121
11,12114,82534,29219,70542,83651,69236,39485,367109,41932,93522,6022,1923,4690
       Cash And Cash Equivalents 
3,827
1,751
1,645
19,058
27,633
100,175
48,357
23,253
40,542
39,338
17,234
30,018
12,445
7,004
7,00412,44530,01817,23439,33840,54223,25348,357100,17527,63319,0581,6451,7513,827
       Short-term Investments 
0
0
0
3,000
2,671
7,338
34,230
10,653
9,197
0
0
0
0
0
000009,19710,65334,2307,3382,6713,000000
       Net Receivables 
1,988
1,667
443
421
1,717
653
1,359
233
367
2,702
907
2,340
1,259
2,780
2,7801,2592,3409072,7023672331,3596531,7174214431,6671,988
       Inventory 
0
0
-1,645
0
913
199
642
0
0
0
1,563
-2,137
0
0
00-2,1371,5630006421999130-1,64500
   > Long-term Assets 
0
3,408
11,554
9,783
11,041
50,105
53,440
41,232
42,607
47,000
46,379
45,651
4,891
5,161
5,1614,89145,65146,37947,00042,60741,23253,44050,10511,0419,78311,5543,4080
       Property Plant Equipment 
592
355
383
243
598
1,136
3,563
3,290
3,014
5,061
4,119
3,248
309
1,830
1,8303093,2484,1195,0613,0143,2903,5631,136598243383355592
       Goodwill 
0
0
0
0
0
1,003
1,040
914
883
883
883
883
0
0
008838838838839141,0401,00300000
       Long Term Investments 
0
0
0
0
68
0
0
0
0
0
0
0
0
0
000000000680000
       Intangible Assets 
10,205
9,625
9,087
9,400
10,266
47,786
48,526
35,594
35,281
35,316
35,288
35,285
864
48
4886435,28535,28835,31635,28135,59448,52647,78610,2669,4009,0879,62510,205
       Long-term Assets Other 
0
183
151
140
109
-1
311
1,161
3,429
5,740
6,089
6,235
3,718
2,941
2,9413,7186,2356,0895,7403,4291,161311-11091401511830
> Total Liabilities 
8,805
6,037
15,058
15,488
17,292
48,052
47,921
30,091
38,710
44,217
35,090
36,304
15,399
26,609
26,60915,39936,30435,09044,21738,71030,09147,92148,05217,29215,48815,0586,0378,805
   > Total Current Liabilities 
2,242
5,921
2,731
3,389
6,053
11,490
11,275
7,945
9,647
11,922
11,834
13,827
10,426
2,932
2,93210,42613,82711,83411,9229,6477,94511,27511,4906,0533,3892,7315,9212,242
       Short-term Debt 
0
0
248
79
134
248
561
636
765
1,359
1,113
902
137
156
1561379021,1131,3597656365612481347924800
       Short Long Term Debt 
0
0
0
106
413
976
207
209
281
192
37
0
0
0
00037192281209207976413106000
       Accounts payable 
1,287
1,086
1,770
2,169
4,042
8,576
8,098
4,800
5,916
6,969
4,736
6,611
4,752
1,243
1,2434,7526,6114,7366,9695,9164,8008,0988,5764,0422,1691,7701,0861,287
       Other Current Liabilities 
664
4,835
67
712
1,100
1,768
1,508
2,283
2,690
3,248
3,776
4,856
4,211
1,024
1,0244,2114,8563,7763,2482,6902,2831,5081,7681,100712674,835664
   > Long-term Liabilities 
0
116
12,328
12,099
11,239
36,562
36,646
22,146
29,063
32,295
23,256
22,477
4,973
23,677
23,6774,97322,47723,25632,29529,06322,14636,64636,56211,23912,09912,3281160
       Long term Debt Total 
0
0
0
0
0
427
917
808
881
3,004
0
0
0
0
00003,00488180891742700000
       Capital Lease Obligations Min Short Term Debt
0
0
-248
-79
-134
-248
174
273
371
2,775
2,488
1,730
118
-156
-1561181,7302,4882,775371273174-248-134-79-24800
       Long-term Liabilities Other 
0
0
0
0
0
0
28,195
19,590
25,187
0
371
164
258
0
0258164371025,18719,59028,195000000
       Deferred Long Term Liability 
0
0
0
925
911
872
805
739
673
607
541
474
408
0
0408474541607673739805872911925000
> Total Stockholder Equity
8,690
840
-1,312
16,898
26,684
111,473
90,884
47,535
55,591
45,619
30,994
43,639
4,317
-10,327
-10,3274,31743,63930,99445,61955,59147,53590,884111,47326,68416,898-1,3128408,690
   Retained Earnings -358,372-349,947-308,997-91,826-74,424-217,778-180,421-124,026-100,313-71,215-36,388-11,287-9,1340
   Accumulated Other Comprehensive Income 
0
0
0
-1,872
19,982
21,205
24,329
23,322
25,667
28,181
30,958
267,734
269,362
315,096
315,096269,362267,73430,95828,18125,66723,32224,32921,20519,982-1,872000
   Capital Surplus 
0
0
0
0
0
158,010
158,010
170,297
206,149
43,349
0
0
0
0
000043,349206,149170,297158,010158,01000000
   Treasury Stock00000000000000



Balance Sheet

All numbers in thousands.




Cash Flow

All numbers in thousands.




Income Statement

All numbers in thousands.